Faculty Opinions recommendation of Sagittal sinus compression is associated with neonatal cerebral sinovenous thrombosis.

AbstractCerebral venous thrombosis is an uncommon event of stroke in childhood. Its origin is multifactorial and often it manifests with nonspecific symptoms that may overlap with underlying predisposing factors. Anti–myelin oligodendrocyte glycoprotein (MOG) antibody syndrome is a group of recently recognized acquired demyelinating diseases that occur more commonly in children, usually, with a favorable outcome. The association between cerebral venous thrombosis and demyelinating syndrome has been reported but their clinical relationship is matter of debate and various hypotheses have been advanced including intravenous (IV) steroid therapy and/or the consequence of a shared inflammatory-thrombotic process. Herein, we report the case of a child with anti-MOG antibody syndromes who developed a thrombosis of the superior sagittal sinus and of the right Trolard's vein.

Download Full-text

Cerebral sinovenous thrombosis during asparaginase treatment

Hämostaseologie ◽

10.1055/s-0037-1619586 ◽

2003 ◽

Vol 23 (03) ◽

pp. 109-112

Author(s):

A. Hirt ◽

C. Zwicky ◽

W.A. Wuillemin ◽

K. Leibundgut

Keyword(s):

Acute Lymphoblastic Leukaemia ◽

Lymphoblastic Leukaemia ◽

Induction Treatment ◽

Pathogenic Mechanisms ◽

Cerebral Sinovenous Thrombosis ◽

Haemorrhagic Infarction ◽

Sinovenous Thrombosis

SummaryA boy (age: 71/12 years) with acute lymphoblastic leukaemia developed thrombosis of the sinus sagitalis superior with secondary haemorrhagic infarction while on induction treatment with vincristine, prednisone, and asparaginase. Based on this report, the potential pathogenic mechanisms are discussed with respect to congenital prothrombotic defects as well as to the role of antileukaemic treatment. Current hypotheses on mechanisms for thromboembolism in children and proposed prophylactic strategies are briefly summarized.

Download Full-text

Management of thrombosis in children and neonates: practical use of anticoagulants in children

Hematology ◽

10.1182/asheducation-2018.1.399 ◽

2018 ◽

Vol 2018 (1) ◽

pp. 399-404 ◽

Cited By ~ 9

Author(s):

Paul Monagle ◽

Fiona Newall

Keyword(s):

Vitamin K Antagonists ◽

Oral Anticoagulants ◽

Direct Oral Anticoagulants ◽

Renal Vein Thrombosis ◽

Therapeutic Agents ◽

Vein Thrombosis ◽

Cerebral Sinovenous Thrombosis ◽

Sinovenous Thrombosis ◽

American Society ◽

Evidence Based Guidelines

Abstract Venous thrombosis (VTE) in children and neonates presents numerous management challenges. Although increasing in frequency, VTE in children and neonates is still uncommon compared with adults. The epidemiology of VTE is vastly different in neonates vs children vs adolescents vs adults. In reality, pediatric thrombosis should be viewed as a multitude of rare diseases (eg, renal vein thrombosis, spontaneous thrombosis, catheter-related thrombosis, cerebral sinovenous thrombosis), all requiring different approaches to diagnosis and with different short- and long-term consequences, but linked by the use of common therapeutic agents. Further, children have fundamentally different physiology in terms of blood flow, developmental hemostasis, and, likely, endothelial function. The American Society ofHematology 2017 Guidelines for Management of Venous Thromboembolism: Treatment of Pediatric VTE provides up-to-date evidence-based guidelines related to treatment. Therefore, this article will focus on the practical use of therapeutic agents in the management of pediatric VTE, especially unfractionated heparin, low-molecular-weight heparin, and oral vitamin K antagonists, as the most common anticoagulants used in children. Direct oral anticoagulants (DOACs) remain in clinical trials in children and should not be used outside of formal trials for the foreseeable future.

Download Full-text